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Abstract
Autoimmune hepatitis (AIH) is a chronic hepatitis of 
unknown etiology which can progress to cirrhosis. Its 
clinical manifestations are highly variable and some-
times follow a fluctuating course. Diagnosis is based on 
characteristic histologic, clinical, biochemical and sero-
logical findings. Anti-inflammatory/immunosuppressive 
treatment frequently induces remission but long-term 
maintenance therapy is often required. Liver transplan-
tation is generally successful in patients with decompen-
sated cirrhosis unresponsive to or intolerant of medical 
therapy.
© 2008 The WJG Press. All rights reserved.
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INTRODUCTION
Autoimmune hepatitis (AIH) is chronic hepatitis of  
unknown etiology, which is thought to occur as a result 
of  escape from normal suppression of  self-reactivity. It 
occurs worldwide in children and adults. Clinical mani-
festations are highly variable and sometimes follow a 
fluctuating course. Diagnosis is based on characteristic 
histologic, clinical, biochemical and serological findings. 
Anti-inflammatory/immunosuppressive treatment in-
duces remission but long-term maintenance therapy is 
often required. Liver transplantation is generally success-
ful in patients with decompensated cirrhosis unrespon-
sive to or intolerant of  medical therapy.
HISTOLOGY
The histologic appearance of  AIH is that of  chronic 
hepatitis, and, although certain changes are characteristic, 
there are no findings specific to the disease. The histo-
logic differential diagnosis of  chronic hepatitis is shown 
in Table 1. Based on the advances in virologic studies and 
refinements of  cholangiographic methods, exclusion of  
other entities has become easier, although co-existence of  
chronic viral hepatitis and AIH may make the diagnosis 
difficult.
The inflammatory component is characterized by a 
mononuclear cell infiltrate, which invades the sharply 
demarcated hepatocyte boundary (limiting plate) sur-
rounding the portal triad and permeates the surrounding 
parenchyma (periportal infiltrate; piecemeal necrosis; 
interface hepatitis) and beyond (lobular hepatitis). It 
may include an abundance of  plasma cells and/or eo-
sinophils, but the portal lesion generally spares the bili-
ary tree. In all but the mildest forms of  AIH, fibrosis 
is present. In advanced disease, fibrosis is extensive 
(bridging fibrosis) and, with distortion of  the hepatic 
lobule and appearance of  regenerative nodules, cir-
rhosis occurs. On occasion, centrizonal disease may be 
present.
The histologic findings differ somewhat comparing 
patients with acute onset AIH to those with an insidi-
ous presentation. Patients presenting with fulminant 
hepatic failure have more interface and lobular hepatitis, 
lobular disarray, hepatocyte necrosis, central necrosis 
and submassive necrosis, but less fibrosis and cirrhosis 
compared to patients presenting with a more chronic 
course[1,2]. Steatosis occurs in a minority of  patients, 
although, given the increasing prevalence of  diabetes, 
dyslipidemia and obesity in many parts of  the world, 
non-alcoholic fatty liver disease may be seen more often 
accompanying AIH. Whether the co-morbidity of  ste-
atosis and/or steatohepatitis accelerate progression of  
disease in AIH is unknown. The prevalence of  cirrhosis 
in patients ≥ 60 years at presentation was found to be 
higher than that in patients ≤ 30 years; when compar-
ing groups of  patients ≥ 60 years with those < 60 years, 
however, no differences were found[2,3]. In patients with 
a spontaneous or pharmacologically-induced remission, 
histologic findings may revert to normal; inflammation 
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may be confined to portal areas; cirrhosis may become 
inactive; and fibrosis may regress or disappear[4].
CLASSIFICATION
The most commonly accepted classification of  AIH is 
based on patterns of  circulating antibodies, although 
there is little evidence to support a role for these anti-
bodies in pathogenesis (Table 2).
Type 1 AIH is most frequently characterized by 
antinuclear antibody (ANA), smooth muscle antibody 
(SMA) and anti-actin antibody (AAA). Titers of  signifi-
cance vary depending on the autoantibody in question 
and assays employed[5]. Anti-actin (IgG anti F actin) anti-
bodies measured by ELISA appear to be more sensitive 
than SMA measured by immunofluorescence[6,7].
The identification of  other circulating autoantibod-
ies, in particular anti-soluble liver antigen/liver-pancreas 
antigen (anti-SLA/LP) and atypical perinuclear anticy-
toplasmic antibody (pANCA) are sometimes helpful in 
diagnosing type 1 disease. Anti-SLA/LP is the most spe-
cific autoantibody detected in type 1 AIH but is found 
in only 10%-30% of  type 1 AIH. Atypical pANCA is 
non-specific, but commonly present. Antimitochondrial 
antibodies (AMA) occur infrequently in type 1 AIH. At 
times AMA may be the sole antibody present and identi-
fy an entity sometimes referred to as AMA-positive AIH 
or the overlap syndrome[8].
Anti-liver/kidney microsome -1 (ALKM-1) and anti-
liver cytosol-1 (ALC-1) antibodies occurring alone or 
together characterize type 2 AIH. Anti-liver cytosol-1 
generally occurs in conjunction with anti-liver/kidney 
microsome-1, but may be the sole autoantibody[9].
Type 1 AIH in Caucasians is associated with the HLA-
DR3 serotype, which is found in linkage disequilibrium 
with HLA-B8 and HLA-A1 and in HLA-DR3-negative 
patients with HLA-DR4. HLA-DR3-associated disease is 
more commonly found in patients ≤ 40 years at presen-
tation[2]. In Japan, where HLA-DR3 is rare, the primary 
association is with HLA-DR4. Polymerase chain reaction 
studies genotyping for HLA-DRB, DQA and DQB have 
confirmed the serologic findings. In children, type 1 AIH 
is commonly associated with the HLA-DRB1*03 and 
HLA-DRB1*13 alleles. Type 2 AIH has been associated 
with HLA-DRB1 as well as HLA-DQB1 alleles[10].
CLINICAL FEATURES
Although there is a female predominance, AIH occurs 
in children and adults of  both sexes in diverse ethnic 
groups worldwide. Type 2 disease, which is seen pre-
dominantly in children and young women, is rare in 
North America[9,10]. Although AIH was thought previ-
ously to be primarily a disease of  the young or middle 
aged, it is now clear that it also occurs in the elderly 
(generally defined as ≥ 60 years of  age)[2,3,11].
The heterogeneous, sometimes fluctuating nature of  
AIH, leads to marked variability in clinical manifesta-
tions. Presentation may be asymptomatic or insidious, 
with mild non-specific symptoms only or may mimic 
acute viral hepatitis. Rarely, AIH presents as fulminant 
hepatic failure[1,12]. Patients with occult disease may have 
undetected cirrhosis and present only when decom-
pensation occurs. The group of  patients now labeled 
as cryptogenic cirrhosis, includes some patients with 
seronegative AIH, underscoring the possibility of  the 
absence of  circulating autoantibodies in AIH[13].
Many patients with an acute presentation have his-
tological evidence of  chronic disease in the liver biopsy, 
indicating that they have had antecedent subclinical dis-
ease, although the duration of  the subclinical anicteric 
course is generally difficult to ascertain. In retrospect, 
a fluctuating course, which had been thought to reflect 
some other diseases, can be identified occasionally. Long 
periods of  subclinical disease may also ensue after pre-
sentation. Recent surveys of  pregnancy in AIH have 
indicated that the initial presentations of  AIH may occur 
not only during pregnancy but in the early post-partum 
period[14,15]. AIH may occur in conjunction with a variety 
of  autoimmune disorders, including celiac disease[16,17]. 
Arthralgia involving small joints is common, and inflam-
matory arthritis may be particularly troublesome.
One presentation of  AIH is in the setting of  medica-
tions, or herbal agents, used for other diseases. It is not 
Table 1  Histologic differential diagnosis of chronic hepatitis
Histologic differential diagnosis
Autoimmune liver disease 
   Autoimmune hepatitis
   Primary biliary cirrhosis
   Primary sclerosing cholangitis
   Variant syndromes
Chronic viral hepatitis
   Chronic hepatitis B
   Chronic hepatitis C
   Chronic hepatitis delta
   Chronic hepatitis due to other viruses
Chronic drug-induced hepatitis
Alpha1-antitrypsin deficiency
Wilson’s disease
Granulomatous hepatitis
Systemic lupus erythematosus
Graft-versus-host disease
Alcoholic steatohepatitis
Nonalcoholic steatohepatitis
Table 2  Classification of autoimmune hepatitis
Disorder Characteristic autoantibodies
Type 1 ANA (antinuclear antibody)
SMA (smooth muscle antibody)
AAA (anti-actin antibody)
Anti SLA/LP (anti-soluble liver antigen/liver-pancreas antigen)
pANCA (atypical perinuclear antineutrophil cytoplasmic 
antibody)
AMA (antimitochondrial antibody)1
Type 2 ALKM-1 (anti-liver/kidney microsome-1)
ALC-1 (anti-liver cytosol-1)
1Occurs infrequently in associat ion with other  characterist ic 
autoantibodies. It may be the sole antibody present in AMA-negative 
autoimmune hepatitis, also referred to as the overlap syndrome.
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clear if  they unmask and/or induce AIH or simply result 
in a drug-induced hepatitis with histological findings that 
mimic AIH. Minocycline and, more recently, statins[18], 
both of  which induce other autoimmune syndromes, 
have been considered as drugs capable of  “triggering” 
AIH. 
Complications of  AIH are those seen in any progres-
sive liver disease and primary hepatocellular carcinoma 
is an expected, although uncommon, consequence[2,19,20]. 
There are no established guidelines for hepatocellular 
carcinoma screening in cirrhosis associated with AIH. A 
reasonable approach would be surveillance with an ultra-
sound and alpha feta-protein every 6-12 mo.
DIAGNOSIS
In the presence of  a compatible histologic picture, the 
diagnosis of  AIH is based on characteristic clinical and 
biochemical findings, circulating autoantibodies and 
abnormalities of  serum globulins. A scoring system, 
proposed and subsequently revised by the International 
AIH Group for experimental purposes to standardize 
diagnosis for clinical trials and population studies, has 
been adopted by clinicians, but found to be problematic 
when applied to individual patients, especially children. 
Thus attempts were undertaken by the International 
AIH Group to devise a less complicated and more ac-
curate system for wider application in clinical practice. A 
scoring system, using autoantibodies, gamma globulins, 
absence of  viral hepatitis and histologic findings from 
patients form a wide geographic distribution, has been 
proposed as a sufficiently sensitive and specific scoring 
system[21].
TREATMENT OF ADULTS WITH AIH
Appropriate management of  AIH can mitigate inflam-
mation, slow progression of  disease, prolong survival, 
improve quality of  life and delay or avoid liver transplan-
tation. However, depending on a variety of  definitions 
of  response, success rates only range from 65% to 80%, 
which leaves a significant number of  patients in need 
of  other than standard treatment. Considerable chal-
lenges still exist in the areas of  initial and maintenance 
regimens, management of  relapse, non-response, drug 
toxicity and intolerance, and non-compliance[8,22].
Standard medications for initial and maintenance 
regimens are still considered to be prednisone (or pred-
nisolone) alone or in combination with azathioprine 
(or 6-mercaptopurine) (Table 3). A recent retrospective 
analysis of  corticosteroid treatment in AIH patients with 
severe and fulminant AIH, suggested that steroids did 
not obviate the need for transplantation and may have 
promoted septic complications[23].
One issue of  treatment of  particular concern is tox-
icity and/or intolerance to 6-mercaptopurine and its pro-
drug azathioprine. The methylation of  6-mercaptopurine 
and 6-thioguanosine 5′-monophosphate is catalyzed by 
thiopurine methyltransferase (TPMT). The genes encod-
ing thiopurine methyltransferase are highly polymorphic. 
Homozygosity and heterozygosity for mutations in 
TPMT genes occur in Caucasian and other populations, 
and these patients may accumulate high levels of  thio-
guanine nucleotides in bone marrow cells. Patients who 
are homozygous for a mutation of  TPMT are at high 
risk for severe toxicity, including death. Patients, who are 
heterozygous for the TMPT mutation, probably have an 
intermediate risk of  toxicity. These findings have led to 
the suggestion that prior to placing patients on azathio-
prine or 6-mercaptopurine, TPMT genotyping may be 
appropriate. Despite reliable methods for TMPT geno-
typing and measurement of  levels of  6-mercaptopurine 
metabolites, their assessment in the clinical management 
of  AIH is not established, and must be evaluated in the 
context of  severity of  disease, as well, as advanced fibro-
sis has been shown to predict azathioprine toxicity[24-26].
Although some patients will remain in remission 
when drug treatment is withdrawn, the majority requires 
long-term maintenance therapy. In general, the response 
is better with milder disease. Adults with cirrhosis at the 
time of  initial biopsy and children, particularly those 
with type 2 disease, rarely stay in remission when treat-
ment is withdrawn and will almost require life-long 
maintenance therapy.
No firm guidelines exist for decisions regarding with-
drawal of  medications because histologic changes may 
lag biochemical responses and a quiescent histologic ap-
pearance and normal biochemical findings while patients 
are still receiving therapy, are not necessarily predictive 
of  continued remission once therapy is withdrawn. Al-
though, in the past, aminotransferase levels ≤ 2 x nor-
mal were proposed as a guideline to reducing medica-
tions, relapse has been shown to be less likely in patients 
who achieve normal transaminase and gamma globulin 
(or IgG) levels[27].
Progress in non-standard treatment for patients with 
inadequate responses or intolerance to therapy with glu-
cocorticosteroids alone or in combination with azathio-
prine or 6-mercaptopurine (including mycophenolate 
mofetil, methotrexate, cyclophosphamide, tacrolimus, 
budesonide and ursodeoxycholic acid) has been slow. In 
view of  the paucity of  trials with non-standard forms of  
therapy most decisions must be based on data obtained 
from case reports and series of  small numbers of  pa-
tients. Cyclosporine, which has been used successfully in 
children to induce remission[28], and tacrolimus are used 
occasionally to treat adults[29,30]. Off-label use of  myco-
phenolate mofetil has become more frequently employed 
in intolerant or non-responsive patients[31,32]. The roles 
of  cyclosporine, tacrolimus, mycophenolate mofetil, 
Table 3  Drugs used in standard treatment of autoimmune 
hepatitis in adults
Regimen Single-drug therapy Combination therapy
Initial Prednisone 20-60 mg/d Prednisone 15-30 mg/d and 
azathioprine 50-100 mg/d
Maintenance Prednisone 5-15 mg/d or 
azathioprine 50-200 mg/d
Prednisone 5-10 mg/d and
azathioprine 50-150 mg/d
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methotrexate, cyclophosphamide, ursodeoxycholic acid, 
budesonide[33,34] and other immunosuppressive medica-
tions have not been established.
AIH patients who develop decompensated cirrhosis 
may require liver transplantation. Five-year patient and 
graft survivals range from 80% to 90%. As in other au-
toimmune liver diseases, recurrence and cirrhosis may 
occur after transplantation[35,36] and mandate modifica-
tions of  the post-transplantion therapeutic regimens. So-
called de novo AIH, also referred to as post-transplantion 
immune hepatitis or graft dysfunction mimicking AIH, 
occurs after liver transplantation for diseases other than 
AIH in adults and children, and may require changes in 
post-transplantion therapy as well[37,38].
ACKNOWLEDGMENTS
I am indebted to Ms. Margo Mertz for editorial assis-
tance. 
REFERENCES
1 Kessler WR, Cummings OW, Eckert G, Chalasani N, Lu-
meng L, Kwo PY. Fulminant hepatic failure as the initial 
presentation of acute autoimmune hepatitis. Clin Gastroen-
terol Hepatol 2004; 2: 625-631
2 Al-Chalabi T, Boccato S, Portmann BC, McFarlane IG, 
Heneghan MA. Autoimmune hepatitis (AIH) in the elderly: 
a systematic retrospective analysis of a large group of con-
secutive patients with definite AIH followed at a tertiary 
referral centre. J Hepatol 2006; 45: 575-583
3 Czaja AJ, Carpenter HA. Distinctive clinical phenotype and 
treatment outcome of type 1 autoimmune hepatitis in the 
elderly. Hepatology 2006; 43: 532-538
4 Czaja AJ, Carpenter HA. Decreased fibrosis during cortico-
steroid therapy of autoimmune hepatitis. J Hepatol 2004; 40: 
646-652
5 Vergani D, Alvarez F, Bianchi FB, Cancado EL, Mackay IR, 
Manns MP, Nishioka M, Penner E. Liver autoimmune serol-
ogy: a consensus statement from the committee for autoim-
mune serology of the International Autoimmune Hepatitis 
Group. J Hepatol 2004; 41: 677-683
6 Frenzel C, Herkel J, Luth S, Galle PR, Schramm C, Lohse 
AW. Evaluation of F-actin ELISA for the diagnosis of auto-
immune hepatitis. Am J Gastroenterol 2006; 101: 2731-2736
7 Granito A, Muratori L, Muratori P, Pappas G, Guidi M, 
Cassani F, Volta U, Ferri A, Lenzi M, Bianchi FB. Antibodies 
to filamentous actin (F-actin) in type 1 autoimmune hepati-
tis. J Clin Pathol 2006; 59: 280-284
8 Krawitt EL. Autoimmune hepatitis. N Engl J Med 2006; 354: 
54-66
9 Bridoux-Henno L, Maggiore G, Johanet C, Fabre M, Vajro 
P, Dommergues JP, Reinert P, Bernard O. Features and 
outcome of autoimmune hepatitis type 2 presenting with 
isolated positivity for anti-liver cytosol antibody. Clin 
Gastroenterol Hepatol 2004; 2: 825-830
10 Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, 
Alvarez F. Linkage disequilibrium between HLA class II 
region and autoimmune hepatitis in pediatric patients. J 
Hepatol 2004; 40: 904-909
11 Strassburg CP, Manns MP. Autoimmune hepatitis in the 
elderly: what is the difference? J Hepatol 2006; 45: 480-482
12 Abe M, Onji M, Kawai-Ninomiya K, Michitaka K, Matsuura 
B, Hiasa Y, Horiike N. Clinicopathologic features of the se-
vere form of acute type 1 autoimmune hepatitis. Clin Gastro-
enterol Hepatol 2007; 5: 255-258
13 Gassert DJ, Garcia H, Tanaka K, Reinus JF. Corticosteroid-
responsive cryptogenic chronic hepatitis: evidence for 
seronegative autoimmune hepatitis. Dig Dis Sci 2007; 52: 
2433-2437
14 Samuel D, Riordan S, Strasser S, Kurtovic J, Singh-Grewel I, 
Koorey D. Severe autoimmune hepatitis first presenting in 
the early post partum period. Clin Gastroenterol Hepatol 2004; 
2: 622-624
15 Schramm C, Herkel J, Beuers U, Kanzler S, Galle PR, Lohse 
AW. Pregnancy in autoimmune hepatitis: outcome and risk 
factors. Am J Gastroenterol 2006; 101: 556-560  
16 Abdo A, Meddings J, Swain M. Liver abnormalities in celiac 
disease. Clin Gastroenterol Hepatol 2004; 2: 107-112
17 Villalta D, Girolami D, Bidoli E, Bizzaro N, Tampoia M, 
Liguori M, Pradella M, Tonutti E, Tozzoli R. High preva-
lence of celiac disease in autoimmune hepatitis detected by 
anti-tissue tranglutaminase autoantibodies. J Clin Lab Anal 
2005; 19: 6-10
18 Alla V, Abraham J, Siddiqui J, Raina D, Wu GY, Chalasani 
NP, Bonkovsky HL. Autoimmune hepatitis triggered by 
statins. J Clin Gastroenterol 2006; 40: 757-761
19 Miyake Y, Iwasaki Y, Terada R, Okamaoto R, Ikeda H, 
Makino Y, Kobashi H, Takaguchi K, Sakaguchi K, Shiratori 
Y. Persistent elevation of serum alanine aminotransferase 
levels leads to poor survival and hepatocellular carcinoma 
development in type 1 autoimmune hepatitis. Aliment Phar-
macol Ther 2006; 24: 1197-1205
20 Meza-Junco J, Montano-Loza AJ, Martinez-Benitez B, 
Kimura-Hayama E. Hepatocellular carcinoma in patients 
with autoimmune liver diseases: two case reports and litera-
ture review. Ann Hepatol 2007; 6: 122-126
21 Hennes EM, Zeniya M, Czaja AJ, Parés A, Dalekos GN, 
Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer H, 
Bianchi FB, Shibata M, Schramm C, de Torres BE, Galle PR, 
McFarlane I, Dienes HP, Lohse AW. Simplified criteria for 
the diagnosis of autoimmune hepatitis. Hepatology 2008; 
9999 (999A):  Epub ahead of print
22 Czaja AJ, Bianchi FB, Carpenter HA, Krawitt EL, Lohse 
AW, Manns MP, McFarlane IG, Mieli-Vergani G, Toda G, 
Vergani D, Vierling J, Zeniya M. Treatment challenges and 
investigational opportunities in autoimmune hepatitis. 
Hepatology 2005; 41: 207-215
23 Ichai P, Duclos-Vallee JC, Guettier C, Hamida SB, Antonini 
T, Delvart V, Saliba F, Azoulay D, Castaing D, Samuel D. 
Usefulness of corticosteroids for the treatment of severe 
and fulminant forms of autoimmune hepatitis. Liver Transpl 
2007; 13: 996-1003
24 Heneghan MA, Allan ML, Bornstein JD, Muir AJ, Tendler 
DA. Utility of thiopurine methyltransferase genotyping and 
phenotyping, and measurement of azathioprine metabolites 
in the management of patients with autoimmune hepatitis. J 
Hepatol 2006; 45: 584-591
25 Czaja AJ, Carpenter HA. Thiopurine methyltransferase de-
ficiency and azathioprine intolerance in autoimmune hepa-
titis. Dig Dis Sci 2006; 51: 968-975
26 Tamori A, Shinzaki M, Kosaka S, Hayashi T, Iwai S, Eno-
moto M, Habu D, Sakaguchi H, Kawada N, Hino M, Shiomi 
S, Nishiguchi S. Thiopurine S-methyltransferase gene poly-
morphism in Japanese patients with autoimmune liver dis-
eases. Liver Int 2007; 27: 95-100
27 Montano-Loza AJ, Carpenter HA, Czaja AJ. Improving the 
end point of corticosteroid therapy in type 1 autoimmune 
hepatitis to reduce the frequency of relapse. Am J Gastroen-
terol 2007; 102: 1005-1012
28 Cuarterolo M, Ciocca M, Velasco CC, Ramonet M, Gonzalez 
T, Lopez S, Garsd A, Alvarez F. Follow-up of children with 
autoimmune hepatitis treated with cyclosporine. J Pediatr 
Gastroenterol Nutr 2006; 43: 635-639
29 Larsen FS, Vainer B, Eefsen M, Bjerring PN, Adel Hansen 
B. Low-dose tacrolimus ameliorates liver inflammation and 
fibrosis in steroid refractory autoimmune hepatitis. World J 
Gastroenterol 2007; 13: 3232-3236
30 Aqel BA, Machicao V, Rosser B, Satyanarayana R, Harnois 
DM, Dickson RC. Efficacy of tacrolimus in the treatment of 
3304      ISSN 1007-9327      CN 14-1219/R      World J Gastroenterol      June 7, 2008     Volume 14     Number 21
www.wjgnet.com
steroid refractory autoimmune hepatitis. J Clin Gastroenterol 
2004; 38: 805-809
31 Inductivo-Yu I, Adams A, Gish RG, Wakil A, Bzowej NH, 
Frederick RT, Bonacini M. Mycophenolate mofetil in auto-
immune hepatitis patients not responsive or intolerant to 
standard immunosuppressive therapy. Clin Gastroenterol 
Hepatol 2007; 5: 799-802
32 Devlin SM, Swain MG, Urbanski SJ, Burak KW. Mycophe-
nolate mofetil for the treatment of autoimmune hepatitis in 
patients refractory to standard therapy. Can J Gastroenterol 
2004; 18: 321-326
33 Csepregi A , Rocken C, Treiber G, Malfertheiner P. 
Budesonide induces complete remission in autoimmune 
hepatitis. World J Gastroenterol 2006; 12: 1362-1366
34 Wiegand J, Schuler A, Kanzler S, Lohse A, Beuers U, Kreisel 
W, Spengler U, Koletzko S, Jansen PL, Hochhaus G, Moll-
mann HW, Prols M, Manns MP. Budesonide in previously 
untreated autoimmune hepatitis. Liver Int 2005; 25: 927-934
35 Gautam M, Cheruvattath R, Balan V. Recurrence of autoim-
mune liver disease after liver transplantation: a systematic 
review. Liver Transpl 2006; 12: 1813-1824
36 Seyam M, Neuberger JM, Gunson BK, Hubscher SG. Cir-
rhosis after orthotopic liver transplantation in the absence of 
primary disease recurrence. Liver Transpl 2007; 13: 966-974
37 Evans HM, Kelly DA, McKiernan PJ, Hubscher S. Progres-
sive histological damage in liver allografts following pediat-
ric liver transplantation. Hepatology 2006; 43: 1109-1117
38 Riva S, Sonzogni A, Bravi M, Bertani A, Alessio MG, Can-
dusso M, Stroppa P, Melzi ML, Spada M, Gridelli B, Colle-
dan M, Torre G. Late graft dysfunction and autoantibodies 
after liver transplantation in children: preliminary results of 
an Italian experience. Liver Transpl 2006; 12: 573-577
                  S- Editor  Li DL    L- Editor  Ma JY    E- Editor  Ma WH
Krawitt EL .  Clinical features of AIH                                                                      3305
www.wjgnet.com
